US Patent

US8058467 — Prostaglandin derivatives

Method of Use · Assigned to Nicox SA · Expires 2029-02-21 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects prostaglandin nitroderivatives for the treatment of glaucoma and ocular hypertension.

USPTO Abstract

Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Drugs covered by this patent

Vyzulta (LATANOPROSTENE BUNOD) · Bausch Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2144`	—	Vyzulta

Patent Metadata

Patent number: US8058467
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-21
Drug substance claim: Yes
Drug product claim: No
Assignee: Nicox SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.